BTC 
ETH 
BNB 
XRP 
SOL 
TRX Veracyte stock falls nearly 40% after resetting Decipher growth expectations
Investor's Business Daily reported that Veracyte stock crashed almost 40% early Thursday. The report attributes the drop to the company resetting growth expectations for its prostate cancer tissue test, Decipher, which the post calls its best-selling test.
Why “Unverified”
- Reported by Investor's Business Daily alone, with no second source or primary confirmation yet
1 independent source group across 1 post · evidence score 52/100. How labels work
What the sources claim
-
Veracyte shares fell almost 40% early Thursday.
“Veracyte stock crashed almost 40% early Thursday”
Investor's Business Daily -
Veracyte reset growth expectations for its Decipher prostate cancer tissue test.
“the company reset growth expectations for its prostate cancer tissue test, Decipher”
Investor's Business Daily
Sources
More in Stocks & Indices
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-11-05 14:30 UTC. Labels are computed from the sources, not by the model.